Yabao Pharma Starts Preclinical Studies on Sepsis Treatment

Yabao Pharma has begun preclinical work on an innovative drug candidate for sepsis based on annexin A5. In 2014, Yabao in-licensed greater China rights to discover, develop and commercialize the technology from Canada's Lawson Health Research Institute. So far, the program has completed discovery validation work. A team led by Dr. Qingping Feng, a scientist at Ontario's Lawson Institute and Western University, discovered the technology. More details.... Stock Symbol: (SHA: 600351) Share this with colleagues: // //